Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Recommendation of Moderate Buy from Analysts

Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price […]

Related Keywords

Alan Herman ,Coherus Biosciences ,Dennism Lanfear ,Steve Glover ,Doug Farrar ,Coherus Biosciences Company Profile ,Eagle Bay Advisors ,Nasdaq ,Hermes Inc ,Maxim Group ,Jump Financial ,Barclays ,Coherus Biosciences Inc ,Get Rating ,Bay Advisors ,Financial Advisors ,Forest Capital Management ,Redwood City ,Coherus Biosciences Daily ,Nasdaq Chrs ,Chrs ,Medical ,Ratings ,Consensus ,